[C:1]([CH:6]([NH:15][CH:16]1[C:22](=[O:23])[NH:21][C:20]2[CH:24]=[CH:25][CH:26]=[CH:27][C:19]=2[N:18]([CH3:28])[CH2:17]1)[CH2:7][CH2:8][C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=1)([O:3][CH2:4][CH3:5])=[O:2].[OH-].[K+].Br[CH2:32][C:33]([O:35][CH3:36])=[O:34]>[Br-].C([N+](CCCC)(CCCC)CCCC)CCC.O1CCCC1>[C:1]([CH:6]([NH:15][CH:16]1[C:22](=[O:23])[N:21]([CH2:32][C:33]([O:35][CH3:36])=[O:34])[C:20]2[CH:24]=[CH:25][CH:26]=[CH:27][C:19]=2[N:18]([CH3:28])[CH2:17]1)[CH2:7][CH2:8][C:9]1[CH:10]=[CH:11][CH:12]=[CH:13][CH:14]=1)([O:3][CH2:4][CH3:5])=[O:2]An ice cold mixture of 84 mg of 3-[N-(1-carboethoxy-3-phenylpropyl)amino]-5-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one, 15 mg of powdered potassium hydroxide and 6.5 mg of tetrabutylammonium bromide in 3 ml of dry tetrahydrofuran is treated with 32 mg of methyl bromoacetate. The reaction is allowed to stir for 3 hr at room temperature. At this time, the solution is filtered and concentrated and the residue dissolved in 20 ml of ethyl acetate. This is washed with 5 ml of water and dried over potassium carbonate. Concentration under reduced pressure affords 3-[N-(1-carboethoxy-3-phenylpropyl)amino]-1-carbomethoxymethyl-5-methyl-1,3,4,5-tetrahydro-1,5-benzo diazepin-2-one.